What is the mechanism of chemotherapy-induced nausea and vomiting and how should it be managed?

Mechanism and Management of Chemotherapy-Induced Nausea and Vomiting

Mechanism

Chemotherapy-induced nausea and vomiting (CINV) occurs through activation of multiple neurotransmitter receptors in the chemoreceptor trigger zone, vomiting center, and gastrointestinal tract. The principal neuroreceptors involved are serotonin (5-HT3) and neurokinin-1 (NK-1) receptors, with additional contributions from dopamine, acetylcholine, corticosteroid, histamine, cannabinoid, and opiate receptors located in the vomiting and vestibular centers of the brain 1. Chemotherapeutic agents or their metabolites activate these receptors, triggering the emetic response. No single final common pathway has been identified, which explains why no single antiemetic agent provides complete protection 1.

Classification of CINV

CINV is categorized into five distinct types 1:

• Acute: Occurs within minutes to several hours after chemotherapy, peaks at 5-6 hours, resolves within 24 hours
• Delayed: Develops >24 hours after chemotherapy; with cisplatin, peaks at 48-72 hours and can last 6-7 days
• Anticipatory: Occurs before treatment as a conditioned response from prior negative experiences (18-57% incidence)
• Breakthrough: Occurs despite prophylactic treatment, requires rescue therapy
• Refractory: Occurs in subsequent cycles when prophylaxis has failed in earlier cycles

Management by Chemotherapy Emetogenic Risk

Highly Emetogenic Chemotherapy (HEC) - >90% Risk

For HEC (including cisplatin), use a three-drug regimen: 5-HT3 receptor antagonist + dexamethasone + NK-1 receptor antagonist (aprepitant) given before chemotherapy 2. This achieves 73% complete response rates versus 52% without the NK-1 antagonist 2.

Specific dosing:

• Day 1: 5-HT3 antagonist (single dose) + dexamethasone 12 mg IV + aprepitant 125 mg PO
• Days 2-3: Dexamethasone 8 mg daily + aprepitant 80 mg daily
• Day 4: Dexamethasone 8 mg 2

Note: Dexamethasone dose is reduced by 40-50% when combined with aprepitant due to drug interactions that double dexamethasone exposure 2.

Moderately Emetogenic Chemotherapy (MEC) - 30-90% Risk

Management differs based on specific regimen:

For anthracycline + cyclophosphamide (AC) combinations: Use the same three-drug regimen as HEC 2. Women receiving AC have particularly high emesis risk, and the three-drug regimen (5-HT3 antagonist + dexamethasone + aprepitant) is strongly recommended with Level I, Grade A evidence 2.

• Day 1: 5-HT3 antagonist + dexamethasone 8 mg IV + aprepitant 125 mg PO
• Days 2-3: Aprepitant 80 mg daily 2

If aprepitant is unavailable, use palonosetron + dexamethasone 2.

For non-AC MEC: Use palonosetron (preferred 5-HT3 antagonist) + dexamethasone 2. Palonosetron demonstrates superior efficacy for delayed emesis compared to other 5-HT3 antagonists (56.8% vs 44.5% complete response days 2-5) 2.

• Day 1: Palonosetron 0.25 mg IV + dexamethasone
• Days 2-3: Dexamethasone for delayed emesis prophylaxis 2

Low Emetogenic Chemotherapy (LEC) - 10-30% Risk

Use a single antiemetic agent on day 1 only: dexamethasone, 5-HT3 antagonist, or dopamine receptor antagonist 2. No routine prophylaxis is needed for days 2-3 2.

Minimal Emetogenic Chemotherapy - <10% Risk

No routine antiemetic prophylaxis is recommended 2.

Delayed Emesis Management

For patients receiving MEC with significant delayed emesis risk who controlled acute emesis, dexamethasone alone is superior to placebo (87% vs 77% free of delayed vomiting) 2. Adding a 5-HT3 antagonist to dexamethasone provides no significant additional benefit and increases constipation 2.

For AC chemotherapy patients, aprepitant 80 mg on days 2-3 is recommended for delayed emesis prevention 2.

Key Risk Factors to Assess

Patient-specific factors that increase CINV risk 1:

• Female sex
• Age <50 years
• History of motion sickness
• Previous CINV episodes
• Low chronic alcohol consumption
• Anxiety levels

Breakthrough and Refractory Management

When standard prophylaxis fails 1:

1. Add dopamine antagonists (metoclopramide 20-30 mg, prochlorperazine 10-20 mg) to existing regimen
2. Consider switching to a different 5-HT3 antagonist (limited evidence but may help)
3. Add anxiolytic agents (lorazepam 1-2 mg) 3
4. Consider olanzapine (emerging evidence shows efficacy) 4, 5
5. Evaluate for other causes: constipation, bowel obstruction, brain metastases, electrolyte disturbances, concurrent medications 3

Anticipatory Emesis

Use lorazepam or similar benzodiazepines plus behavioral techniques 3. This is primarily a conditioned response requiring psychological intervention alongside pharmacotherapy.

Critical Implementation Points

• Prophylaxis is more effective than rescue treatment - always give antiemetics before chemotherapy 1
• Oral and IV formulations of 5-HT3 antagonists are equally effective 2
• No clinically relevant differences exist between 5-HT3 antagonists (ondansetron, granisetron, dolasetron, tropisetron) except palonosetron, which has superior delayed emesis control 2
• Nausea is harder to control than vomiting and often persists despite effective vomiting prevention 1
• Younger women with breast cancer are particularly prone to nausea and require aggressive prophylaxis 1

Common Pitfalls

1. Under-dosing dexamethasone when not using aprepitant (should be 20 mg for HEC, 8 mg for AC)
2. Forgetting to reduce dexamethasone dose by 50% when combining with aprepitant 2
3. Not providing delayed emesis prophylaxis for days 2-4 after HEC or AC chemotherapy
4. Treating all MEC the same - AC regimens require NK-1 antagonist, non-AC regimens do not 2
5. Relying on patient spontaneous reports - 35% of physicians do this, but structured assessment at specific timepoints is essential 6